PT - JOURNAL ARTICLE AU - David A. Swan AU - Ashish Goyal AU - Chloe Bracis AU - Mia Moore AU - Elizabeth Krantz AU - Elizabeth Brown AU - Fabian Cardozo-Ojeda AU - Daniel B Reeves AU - Fei Gao AU - Peter B. Gilbert AU - Lawrence Corey AU - Myron S. Cohen AU - Holly Janes AU - Dobromir Dimitrov AU - Joshua T. Schiffer TI - Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021 AID - 10.1101/2020.12.13.20248120 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.13.20248120 4099 - http://medrxiv.org/content/early/2020/12/14/2020.12.13.20248120.short 4100 - http://medrxiv.org/content/early/2020/12/14/2020.12.13.20248120.full AB - Ongoing SARS-CoV-2 vaccine trials assess vaccine efficacy against disease (VEDIS), the ability of a vaccine to block symptomatic COVID-19. They will only partially discriminate whether VEDIS is mediated by preventing infection as defined by the detection of virus in the airways (vaccine efficacy against infection defined as VESUSC), or by preventing symptoms despite breakthrough infection (vaccine efficacy against symptoms or VESYMP). Vaccine efficacy against infectiousness (VEINF), defined as the decrease in secondary transmissions from infected vaccine recipients versus from infected placebo recipients, is also not being measured. Using mathematical modeling of data from King County Washington, we demonstrate that if the Moderna and Pfizer vaccines, which have observed VEDIS>90%, mediate VEDIS predominately by complete protection against infection, then prevention of a fourth epidemic wave in the spring of 2021, and associated reduction of subsequent cases and deaths by 60%, is likely to occur assuming rapid enough vaccine roll out. If high VEDIS is explained primarily by reduction in symptoms, then VEINF>50% will be necessary to prevent or limit the extent of this fourth epidemic wave. The potential added benefits of high VEINF would be evident regardless of vaccine allocation strategy and would be enhanced if vaccine roll out rate is low or if available vaccines demonstrate waning immunity. Finally, we demonstrate that a 1.0 log vaccine-mediated reduction in average peak viral load might be sufficient to achieve VEINF=60% and that human challenge studies with 104 infected participants, or clinical trials in a university student population could estimate VESUSC, VESYMP and VEINF using viral load metrics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1AI068635 and R37AI054165 to Dr. Gilbert) and (R01 AI121129-04 to Dr. Schiffer). Dr. Schiffer and Dimitrov received CDC funds to assist in modeling the COVID pandemic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for our mathematical model will be provided immediately upon request.